



Overview of Medicines market/ COVID-19 response DAY 1 – 6 Dec. 2021

Akthem Fourati,

MNC, UNICEF Supply Division

PHARMACEUTICAL SUPPLY CHAIN COVID IMPACT

Market Conditions



Program Implementation- Impact on Supply

Existing Programs

Fiscal space constrained with the economic impact of COVID-19.

Management of budget overruns, delayed implementation of campaigns, critical care needs shooting up.

Community based outreach programs e.g SMC

Other programs like ART – Multi month dispensing used

Evolution of National protocols for Covid management

Candidate Therapeutics not supported by WHO recommendation

- Hydroxychloroquine
- Chloroquine
- Lopinavir/ritonavir
- Azithromycin
- Remdesivir
- Ivermectin etc

WHO recommendation/ Pipeline


- Corticosteroids
- Neutralizing Monoclonal Antibodies
- IL-6 receptor blockers
- Novel Antivirals

GLOBAL EFFORTS IN ADDRESSING SUPPLY AND PROCUREMENT CHALLENGES

- Diversification of supplier base, including geographically
- Strategic inventory for pharmaceuticals in the warehouse
- Close engagement with the Industry, addressing issues as they emerge
- Supply Financing : UNICEF Supply Financing Facility for COVID19 (SFF), ACT- A Partnership, Multilateral development banks working closely with governments
- Coordination : Access to COVID19 Tools Accelerator (ACT –A), Continuous program implementations- guidance shared
- More information for UNICEF see link below <u>https://www.corecommitments.unicef.org/latest-covid-19-guidance</u>

WHO GUIDANCE ON COVID THERAPEUTICS

RECOMMENDED COVID19 THERAPEUTICS



- 1. Corticosteroids Dexamethasone
- 2. Oxygen
- 3. Neutralizing monoclonal antibodies (casirivimab and imdevimab)
- 4. Interleukin (IL) 6 Receptor Blockers Tocilizumab and Sarilumab),

UNICEF continues to work with industry to secure access, affordable pricing and availability to meet patient and clinical demand

COUNTRIES RECEIVING COVID THERAPEUTICS (DEXA) FROM UNICEF WITH SFF SUPPORT



unicef

Thank you.



colline /